Back to Companies
Allogene Therapeutics, Inc.
ALLONasdaqCIK: 0001737287
Over the 21 most recent insider filings, Allogene Therapeutics, Inc. (ALLO) has seen activity from 13 distinct insiders — all of them on the sell side. The activity is heavily weighted toward selling: $0 bought versus $473.4K sold, net sales of $473.4K. Chang David D (President and CEO, Director) is the most active by dollar volume, and the single largest transaction was $2.8M by Chang David D. All figures are drawn from official SEC Form 3, 4, and 5 disclosures and update as new filings arrive.
Total Volume
$10.5M
Purchases
$0
Sales
$473.4K
Unique Insiders
13
Recent Insider Trades
21 loaded
| Jul 6 | ALLO Allogene Therapeutics, Inc. | Roberts Zachary | President and CEO | Award | $1.0M |
| Jun 23 | ALLO Allogene Therapeutics, Inc. | MESSEMER DEBORAH M. | Director | Award | $0 |
| Jun 23 | ALLO Allogene Therapeutics, Inc. | Humer Franz B | Director | Award | $0 |
| Jun 23 | ALLO Allogene Therapeutics, Inc. | Barrett Elizabeth A. | Director | Award | $0 |
| Jun 23 | ALLO Allogene Therapeutics, Inc. | Kazam Joshua A | Director | Exercise | $0 |
| Jun 23 | ALLO Allogene Therapeutics, Inc. | Mayo Stephen | Director | Award | $288.8K |
| Jun 23 | ALLO Allogene Therapeutics, Inc. | SATO VICKI L | Director | Award | $0 |
| Apr 23 | ALLO Allogene Therapeutics, Inc. | Yoshiyama Annie | SVP, Finance | Sell | $22.1K |
| Apr 2 | ALLO Allogene Therapeutics, Inc. | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Sell | $7.2K |
| Mar 4 | ALLO Allogene Therapeutics, Inc. | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Sell | $18.5K |
| Feb 4 | ALLO Allogene Therapeutics, Inc. | Chang David D | President and CEO, Director | Sell | $171.5K |
| Feb 4 | ALLO Allogene Therapeutics, Inc. | Belldegrun Arie | Director | Award | $1.7M |
| Feb 4 | ALLO Allogene Therapeutics, Inc. | Roberts Zachary | EVP of R&D | Sell | $63.2K |
| Feb 4 | ALLO Allogene Therapeutics, Inc. | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Sell | $13.1K |
| Feb 4 | ALLO Allogene Therapeutics, Inc. | Douglas Earl Martin | SVP, General Counsel | Sell | $40.3K |
| Feb 4 | ALLO Allogene Therapeutics, Inc. | Yoshiyama Annie | SVP, Finance | Sell | $7.2K |
| Feb 4 | ALLO Allogene Therapeutics, Inc. | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Sell | $42.2K |
| Jan 23 | ALLO Allogene Therapeutics, Inc. | Roberts Zachary | EVP of R&D | Sell | $41.0K |
| Dec 22 | ALLO Allogene Therapeutics, Inc. | Kazam Joshua A | Director | Exercise | $0 |
| Nov 19 | ALLO Allogene Therapeutics, Inc. | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Sell | $959 |
| Oct 23 | ALLO Allogene Therapeutics, Inc. | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Sell | $46.2K |
21 filings